Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.

Orphanet J Rare Dis · 2016 · PMC4928260 · PMID 27356758

Europe PMC DOI

hedged sentence

0.1499

closest p · 3.0× alpha

0.1499

boldest claim

The sentences

showed a trendp = 0.1499not close (p > 0.1)

However, analysis of the clinical presentation revealed that patients under agalsidase-beta tended to be older ( p = 0.1371) and showed a trend towards a longer ERT duration ( p = 0.1499) than patients receiving agalsidase-alfa (Additional file 3 : Table S3).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.